Business
Abeona Therapeutics® Announces Date of First Quarter Financial Results
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only web
About this update from Abeona Therapeutics Inc.
[{"type":"image","alt":"Abeona Therapeutics Inc.","displaySize":"","headline":null,"caption":"Abeona Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":256,"height":181,"url":"https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HRLXSFjGp4rPpBccsBYqcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5Nw--/https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d","width":256,"height":181}},"lazy":false},{"type":"text","content":"CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress.","length":260,"tagName":"p"},{"type":"text","content":"The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the call.","length":478,"tagName":"p"},{"type":"text","content":"About Abeona Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.","length":825,"tagName":"p"},{"type":"text","content":"ZEVASKYN®, Abeona Assist®, ...